Thrombolytic therapy in acute occlusion of the intracranial internal carotid artery bifurcation

AJNR Am J Neuroradiol. 1995 Nov-Dec;16(10):1977-86.

Abstract

Purpose: To evaluate efficacy and clinical benefit of early thrombolytic therapy in intracranial internal carotid artery occlusion.

Methods: Thirty-two patients (mean age, 56 years) with acute intracranial internal carotid artery occlusion were studied clinically and with CT and angiography before and after thrombolytic therapy with intravenous alteplase (n = 16), superselective intraarterial alteplase (n = 8), and superselective intraarterial urokinase (n = 8).

Results: Initial CT showed a large parenchymal hypodensity in 11 (34%) patients, a small hypodensity in 15 (47%) patients, and no hypodensity in 6 (19%) patients. Recanalization after thrombolytic therapy was observed in 4 patients (12.5% in each treatment group). Follow-up CT showed six hemorrhagic infarcts and four parenchymal hematomas unrelated to recanalization, alteplase, or urokinase administration, but commonly associated with intraarterial treatment. Clinical outcome was fatal in 53%, poor in 31%, and moderate or good in 16% of the patients. Outcome was equal in different treatment groups and closely linked to both the quality of leptomeningeal collaterals and the extent of parenchymal hypodensity on the first CT.

Conclusion: Because intravenous or intraarterial treatment with alteplase or urokinase fails to recanalize the vascular obstruction, it does not improve the prognosis of intracranial internal carotid artery occlusion over that of the natural course. Improved results may be possible with novel recanalization techniques.

MeSH terms

  • Adult
  • Aged
  • Brain Ischemia / diagnostic imaging
  • Brain Ischemia / drug therapy
  • Brain Ischemia / mortality
  • Carotid Artery Thrombosis / diagnostic imaging
  • Carotid Artery Thrombosis / drug therapy*
  • Carotid Artery Thrombosis / mortality
  • Carotid Artery, Internal / diagnostic imaging
  • Carotid Artery, Internal / drug effects
  • Cerebral Infarction / diagnostic imaging
  • Cerebral Infarction / drug therapy
  • Cerebral Infarction / mortality
  • Collateral Circulation / drug effects
  • Collateral Circulation / physiology
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Intracranial Embolism and Thrombosis / diagnostic imaging
  • Intracranial Embolism and Thrombosis / drug therapy*
  • Intracranial Embolism and Thrombosis / mortality
  • Male
  • Meninges / blood supply
  • Middle Aged
  • Radiography
  • Survival Rate
  • Thrombolytic Therapy*
  • Tissue Plasminogen Activator / adverse effects
  • Tissue Plasminogen Activator / therapeutic use*
  • Treatment Outcome
  • Urokinase-Type Plasminogen Activator / adverse effects
  • Urokinase-Type Plasminogen Activator / therapeutic use*

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator
  • Urokinase-Type Plasminogen Activator